Scientific publications

Fluvastatin in the treatment of hypercholesterolemia in renal transplantation

Gómez G., Álvarez M.L., Errasti P., Lavilla F.J., García N., Ballester B., García I., Purroy A.
Renal Unit. University of Navarra. Pamplona (Spain)

Magazine: Transplantation Proceedings

Date: Sep 1, 1999

Nephrology [SP]

Atherosclerotic cardiovascular disease (ACD) in renal transplant patients (RTP) is the main cause of death, roughly 50–60%. In nondiabetic RTP the incidence of death because of ischemic heart disease is approximately six times higher, and in diabetic RTP 20 times higher, than in the general population.

Risk factors for the development of vascular disease in RTP include diabetes, hypertension, hyperlipidemia, smoking, and immunosuppressive regimens. Hyperlipidemia is a well-known risk factor for ACD, especially the increments of total cholesterol (TC) and low-density lipoprotein (LDLc). Moreover hyperlipidemia is involved in the development of chronic allograft rejection. Pathogenesis of hyperlipidemia include cyclosporine, renal dysfunction, diabetes, proteinuria, prednisone dose, obesity, age and gender, and the use of certain beta-blocking or diuretic drugs. The HMG-CoA reductase inhibitors are the most powerful drugs for lowering LDLc and TC in hyperlipidemic patients.

We have studied the effect of fluvastatin (FV), a HMG-CoA reductase inhibitor, on hypercholesterolemia of RTP.

CITATION  Transplant Proc. 1999 Sep;31(6):2326-7



The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra